Glenmark Pharma bags USFDA nod for generic version of Cleocin Hydrochloride Capsules
Clindamycin Hydrochloride capsules are used for the treatment of bacterial infections of the skin, blood, lungs, female reproductive organs, and internal organs.
Mumbai: Glenmark Pharmaceuticals Limited has received final approval from the United States Food & Drug Administration (U.S. FDA) for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg.
The product is the generic version of Cleocin Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg, of Pfizer Inc.
Clindamycin Hydrochloride capsules are used for the treatment of bacterial infections of the skin, blood, lungs, female reproductive organs, and internal organs. This medicine may be given to patients who have had an allergic reaction to penicillin. Clindamycin will not work for flu, colds, or other virus infections.
Glenmark’s Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. According to IQVIA sales data for the 12-month period ending January 2023, the Cleocin Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg market achieved annual sales of approximately $33.6 million*.
Glenmark’s current portfolio consists of 181 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Read also: Glenmark Gets CDSCO panel nod for Phase IV CT of Fosnetupitant, Palanosetron FDC drug
Glenmark Pharmaceuticals Ltd. is an innovation-driven, global pharmaceutical company with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 worldclass manufacturing facilities spread across 4 continents, and operations in over 80 countries. The company has been Great Place To Work Certified in India, in 2023.
Read also: Glenmark Pharma unveils triple FDC Zita-PioMet for Type 2 diabetes in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.